Plus Therapeutics Q1 2024 net loss $3.3M; cash $3M; secures up to $19.25M financing

PLUS THERAPEUTICS, INC.

2024-Q1 EPS reported -$0.75 revenue$1,677,000

Net loss of $3.3M ($0.75 per share) vs $4.8M ($2.07) in Q1 2023; grant revenue rose to $1.7M from $0.5M.
Cash balance $3.0M at March 31, 2024, down from $8.6M at December 31, 2023.
Closed private placement for initial $7.25M with potential total of $19.25M from healthcare funds and insiders.
Received $3M Department of Defense grant recommendation for Phase 1 rhenium obisbemeda trial in pediatric brain cancer.
Acquired exclusive rights to CNSide leptomeningeal metastases diagnostic; reported positive top-line FORESEE trial data.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

PLUS THERAPEUTICS, INC. reported the first quarter ended March 31, 2024 results: revenue $1.7 million in grant revenue, net income $3.3 million, EPS $(0.75) per share.

Period: the first quarter ended March 31, 2024
Revenue: $1.7 million in grant revenue
Net income: $3.3 million
EPS: $(0.75) per share
Result: reported results

Exact text from the filing

FIRST QUARTER 2024 FINANCIAL RESULTS • The Company’s cash balance was $3 million at March 31, 2024 compared to $8.6 million at December 31, 2023. • The Company recognized $1.7 million in grant revenue in the first quarter of 2024 compared to $0.5 million in the first quarter of 2023, which represents CPRIT’s share of the costs incurred for the Company’s rhenium ( 186 Re) obisbemeda development for the treatment of patients with LM • Total operating loss for the first quarter of 2024 was $3.3 million compared to $4.8 million in the same period of 2023. The decrease was primarily due to increased grant revenue • Net loss for first quarter of 2024 was $3.3 million, or $(0.75) per share, compared to a net loss of $4.8 million, or $(2.07) per share, for the same period the prior year

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

PLUS THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0000950170-24-060399

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.